SEC Form 4 · accession 0001179110-17-000756
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Athena Countouriotis
Officer — SVP and Chief Medical Officer
Period of report
Jan 5, 2017
Accepted (ET)
Jan 9, 2017 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2017 | M | 7,500 | $0.00 | A | 27,481 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Jan 5, 2017 | M | 7,500 | D | — | — | Common Stock | 7,500 | 15,000 | D |
Explanation of responses
- F1This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.